Pharma Wholesale and Distribution Market Forecasts 2016-2026

医薬品卸売・物流の世界市場予測2016-2026

◆タイトル:Pharma Wholesale and Distribution Market Forecasts 2016-2026
◆商品コード:VGAIN61117
◆調査・発行会社:visiongain
◆発行日:2016年9月
◆ページ数:272
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥303,848見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥455,848見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥759,848見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、医薬品卸売・物流の世界市場について調査・分析し、医薬品卸売・物流の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
1. レポート概要

2. 医薬品卸売・物流の概要

3. 医薬品卸売・物流の世界市場:2015-2026

4. 医薬品卸売・物流産業:主要国市場2015-2026

5. 主要な医薬品卸売業者・物流業者2016:現在および将来の業績

6. 医薬品卸売・物流市場の定性分析

7. 調査インタビュー

8. 結論

Pharma Wholesaling and Distribution – Analysis of Companies, Trends and Future Revenues to Benefit Your Influence
What does the future hold for drug wholesale and distribution (W&D) services? Discover revenue predictions there to 2026. And explore trends in those services and technologies, assessing prospects and finding opportunities to benefit your work and authority.

In visiongain’s new report you gain revenue forecasts at overall world market, submarket, company and national level. There you assess potentials for expanding revenues. See where that industry’s best prospects lie.

Please read on to explore activities of distributors and wholesalers of pharmaceuticals, discovering what that business’s future could be worth.

Forecasts and other analysis to benefit your knowledge of medical distribution systems
Is finding pharma wholesale and distribution information a challenge? Avoid falling behind in knowledge on the supply of medicines. With our data, help your research, analyses and decisions. Also save time and benefit your reputation for commercial insight.

Besides revenue forecasting, our new investigation shows historical data, growth rates and market shares. That industry changes in 2016 through mergers and acquisitions. In our study discover what is happening, helping you stay ahead.

There you find original quantitative and qualitative analyses, exploring business outlooks and developments. In our 272 page study you gain 83 tables, 98 charts and a research interview.

Discover where revenues can increase most. In the following sections you see how our new study benefits your knowledge on the supply chain for human medicines.

Prospects for that world market and submarkets – discover what revenues are possible
Our new report shows revenue to 2026 for the overall world market. It also gives you forecasts for three submarkets in the distributing and wholesaling of medicines:
• Original-branded pharmaceuticals – small molecules and biological drugs
• Generic prescription medicines – generics
• Other products related to pharmaceutical supply.

Discover pharma distribution chain revenues. How will that wholesaling and distributing market grow? Which parts will prosper most, and why? With our data you assess potential sales and revenue growth. See what is possible from 2016.

In our study you also discover geographical revenue predictions.

Sales potentials for medical wholesaling and distributing in leading countries
Developments worldwide expand the pharma W&D market, especially rising demand for medicines in fast-emerging countries. China, India, Russia and Brazil underpin revenue growth. Discover how domestic and international suppliers expand business.

In developed and developing regions opportunities for drug wholesalers and other medical suppliers will occur from 2016. Pharmacies also stand to gain. See where, why and how, discovering what is possible.

Our report shows you individual revenue forecasts to 2026 for 11 national markets:
• United States
• Japan
• Germany, France, United Kingdom, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC).

There you discover progress and outlooks. You assess the W&D industry’s future, seeing developments and finding their meaning.

Forecasting and other analyses for leading pharma supply chain intermediaries
How will prominent W&D companies perform to 2026? Our work shows you individual revenue forecasts for 10 leading pharma wholesalers and distributors:
• McKesson
• Cardinal Health
• AmerisourceBergen
• Walgreens Boots Alliance
• MEDIPAL HOLDINGS
• The PHOENIX Group
• SINOPHARM
• Alfresa Holdings
• Suzuken
• Shanghai Pharmaceutical Holdings.

With our sales predictions you assess organisations, seeing activities, results, changes and outlooks. You find what is happening, exploring trends, competition, challenges and opportunities.

That way you investigate the pharma W&D industry’s prospects, discovering progress and finding what it means. Our study explains the issues affecting that industry’s present and future.

Forces and changes affecting the supply of medicines through distribution networks
Our report explains issues, events and shifts affecting that industry and market from 2016, including these influences:
• Roles of pharmaceutical wholesalers – activities, changes and prospects
• Revenues, costs and profits – find results, opportunities and sales potentials
• Direct-to-pharmacy (DTP) activities – assess how those developments affect suppliers, clients and the W&D market
• Full-line wholesalers (FLWs), short-line wholesalers (SLWs) and the drug distribution chain, including logistical service providers
• Technologies and services – progress in supplying pharmacies, clinics and hospitals, serving healthcare professionals, governments, payers and patients
• Forward buying, fee-for-service systems and the rise of retail pharmacies.

Our investigation also discusses other aspects of that industry, including these forces:
• Alliance Boots merging with Walgreens, McKesson’s acquisition of Celesio and other consolidation – explore deals changing that industry
• Parallel trade – activities, policies, challenges and effects
• Inventory management agreements, clawback, reimbursement and discounts
• Rise of specialty medicines, including biologics, vaccines and biosimilars – opportunities for intermediaries, including cold chain distribution networks
• Actions against drug counterfeiting – security of pharmaceutical supply chains
• Changes to regulations and healthcare budgets – policies affecting trade.

That way you assess technological, economic, social and political questions, exploring news and outlooks for the medical supply chain. You also analyse that industry’s strengths, weaknesses, opportunities and threats. See what the future holds.

Value of the overall pharma W&D market in 2020 – what revenue is possible?
Visiongain forecasts that the overall pharmaceutical wholesale and distribution industry will achieve revenue of $1,357 billion worldwide in 2020. That market will rise further – see what gains are possible.

Wholesaling and distributing services will experience steady revenue growth from 2016 to 2026, adapting to driving and restraining forces – changes, opportunities and threats. Find how high that industry’s turnover can go, also exploring what influences its revenues and profits.

So discover, with our data, revenue streams and opportunities for intermediaries in the pharma supply chain. There you explore established and rising companies. Their market holds great potential from 2016 for investments, progress and expansion.

6 main ways Pharma Wholesale and Distribution Market Forecasts 2016-2026 helps
In our new analysis you gain the following knowledge to benefit your analyses, plans, presentations and authority:
• World pharma W&D revenue to 2026 – discover that industry’s overall sales potential from 2016
• 3 world-level submarkets’ revenues to 2026 – investigate potentials, finding the most promising segments for developments, investments and sales
• 10 top companies’ revenues to 2026 – discover forecasts for leading players, seeing how they develop their businesses, compete and succeed
• 11 national market forecasts to 2026 in the Americas, Europe and Asia – explore top countries for revenues, demand and potential sales expansion
• Activities of leading organisations – analyse participants’ financial results, strategies, capacities, partnerships, mergers and acquisitions
• Competition and opportunities – explore what shapes that industry’s future, assessing prospects for sustaining and developing business.

That report, by visiongain’s in-house analysts in the UK, gives knowledge with the purpose of saving you effort and time, making your work easier and more likely to succeed. You gain analysis leading companies depend on.

Data found nowhere else – benefit your research, decisions, plans and influence
Our investigation gives independent analysis. There you receive discussions and predictions found only in our report, seeing where prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. Discover there how you could benefit your research, analyses, plans and decisions, also saving time and getting recognition for commercial insight.

Our analysis costs only a tiny fraction of potential profits from your exploring and harnessing the pharma W&D market. Assess its changes and growth potentials.

Forecasts for pharmaceutical supply – stay ahead by trying our analysis now
Our new study is for everyone analysing the supply of human medicines. In that work you explore results, trends, opportunities and revenue predictions, seeing what is possible. Avoid missing out. Stay ahead by getting our report here now.

【レポートの目次】

1. Report Overview
1.1 Global Pharma Wholesale and Distribution Industry and Market Overview
1.2 Pharma Wholesale and Distribution Industry Structure
1.3 Benefits of This Report
1.4 How This Report Delivers
1.5 Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Pharma Wholesale and Distribution
2.1 The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry
2.1.1 Full-Line Wholesalers (FLWs)
2.1.2 Short-Line Wholesalers (SLWs)
2.2 The Chain of Distribution: Wholesalers vs. Logistic Service Providers
2.2.1 Secondary Wholesalers
2.2.2 Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent
2.2.3 Major Wholesalers: Distribution of a Large Number of Products to Generate High Profits
2.2.4 Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain
2.2.5 Pharmacy Benefit Managers
2.3 Generative Revenue and Profit
2.3.1 Forward Buying to Avoid Price Increases
2.3.2 Fee-for-Service: A Clear Pricing Structure
2.3.2.1 Inventory Management Agreements
2.3.3 Discounts: Incentives for Prompt Payment or Bulk Purchases
2.3.4 Reimbursement and Wholesalers
2.3.5 Clawback: The Recovery of Reimbursement Costs by Governments
2.3.6 Parallel Trade: Different Attitudes in Europe and the US

3. The World Pharmaceutical Wholesale and Distribution Market: 2015-2026
3.1 The World Pharmaceutical Wholesale and Distribution Market in 2015, Restricted by Government Price Reductions and Generic Substitution
3.2 The Pharmaceutical Wholesale and Distribution Industry: World Market Forecast, 2015-2026
3.3 Branded and Generic Drugs: Revenue vs. Profit, 2015-2026
3.3.1 Branded and Generic Drugs: Revenue Generation, 2015
3.3.2 Branded Drugs: Revenue Forecast, 2015-2026
3.3.3 Generic Drugs: Revenue Forecast, 2015-2026

4. Pharmaceutical Wholesale and Distribution Industry: Leading National Markets, 2015-2026
4.1 The Leading National Markets: the US Dominates in 2015
4.2 The Future of the Leading National Markets: Will the US Continue to Dominate the Market?
4.3 The US Pharma Wholesale and Distribution Market
4.3.1 The Budget Control Act and its Effect on the US Wholesale and Distribution Industry
4.3.2 Legislation to Prevent Counterfeit Drugs Can Differ Between States
4.3.3 An Increase in Fee-For-Service Activity
4.3.4 Pharma Wholesale and Distribution Market in the US: Market Forecast, 2015-2026
4.4 The Leading European (EU5) Pharma Wholesale and Distribution Markets
4.4.1 The Difference Between the US and European Markets
4.4.2 State-Funded Healthcare and Reimbursement
4.4.3 EU5: Market Forecast, 2015-2026
4.4.4 Germany: Pharma Wholesale and Distribution Market, 2015
4.4.4.1 Healthcare Reform
4.4.4.2 Germany: Reform of AMNOG Pharmaceutical Rebate Law
4.4.4.3 Germany Pharma Wholesale and Distribution Market Forecast, 2015-2026
4.4.5 France: Pharma Wholesale and Distribution Market, 2015
4.4.5.1 France: Social Security Finance Bill 2015
4.4.5.2 France: Pharma Wholesale and Distribution Market Forecast, 2015-2026
4.4.6 Italy: Pharma Wholesale and Distribution Market, 2015
4.4.6.1 Italy: Pharma Wholesale and Distribution Market Forecast, 2015-2026
4.4.7 Spain: Pharma Wholesale and Distribution Market, 2015
4.4.7.1 Spain: Pharma Wholesale and Distribution Market Forecast, 2015-2026
4.4.8 UK: Pharma Wholesale and Distribution Market, 2015
4.4.8.1 Price Cuts in the UK
4.4.8.2 UK: Pharma Wholesale and Distribution Market Forecast, 2015-2026
4.5 Japan: Pharma Wholesale and Distribution Market, 2015
4.5.1 Drug Pricing and Performing Fees in Japan
4.5.2 Japan: Pharma Wholesale and Distribution Market Forecast, 2015-2026
4.6 China: Pharma Wholesale and Distribution Market, 2015
4.6.1 China: Leading Pharma Wholesale and Distribution Companies, 2015
4.6.2 China: Pharma Wholesale and Distribution Market Forecast, 2015-2026
4.7 Brazil: Pharma and Wholesale Distribution Market, 2015
4.7.1 Drug Price Controls in Brazil
4.7.2 Brazil: Leading Pharma Wholesale and Distribution Companies, 2015
4.7.3 Brazil: Pharma Wholesale and Distribution Market Forecast, 2015-2026
4.8 India: Pharma Wholesale and Distribution Market, 2015
4.8.1 India: Pharma Wholesale and Distribution Market Forecast, 2015-2026
4.9 Russia: Pharma Wholesale and Distribution Market, 2015
4.9.1 Drug Pricing Controls in Russia
4.9.2 Market Trends in Russia
4.9.3 Russia: Pharma Wholesale and Distribution Market Forecast, 2015-2026
4.10 Conclusion

5. Leading Pharma Wholesalers and Distributors in 2016: Current and Future Performance
5.1 The Leading Pharma Wholesalers and Distribution Companies in 2015
5.2 Revenue vs. Profit
5.3 Leading Pharma Wholesale and Distribution Companies: Grouped Forecasts, 2015-2026
5.4 McKesson: The Oldest and Largest Healthcare Services Company in the US
5.4.1 McKesson: Historical Performance, 2010-2015
5.4.2 Future Strategies: Consummate Acquisitions to Complement Existing Business or Expand Businesses
5.4.3 McKesson: Revenue Forecast, 2015-2026
5.5 Cardinal Health: The World’s Third Largest Pharma Wholesaler
5.5.1 Cardinal Health: Historical Performance, 2010-2015
5.5.2 Will CVS Joint Venture and Acquisitions Stimulate Future Growth?
5.5.3 Cardinal Health: Revenue Forecast, 2015-2026
5.6 AmerisourceBergen: Second Largest Global Pharma Wholesaler and Distributor
5.6.1 AmerisourceBergen: Historical Performance, 2015
5.6.2 Will Contracts with Walgreens and Alliance Boots Drive Future Growth?
5.6.3 AmerisourceBergen: Revenue Forecast, 2015-2026
5.7 Walgreens Boots Alliance: The Largest Drugstore Chain in the US and Global Wholesale and Distribution Network
5.7.1 Walgreens Boots Alliance: Historical Performance, 2011-2015
5.7.2 Acquisitions and Future Strategies of Walgreens Boots Alliance
5.7.3 Walgreens Boots Alliance: Revenue Forecast, 2015-2026
5.8 MEDIPAL HOLDINGS CORPORATION: Japan’s Leading Pharmaceutical Wholesaler
5.8.1 MEDIPAL HOLDINGS CORPORATION: Historical Performance, 2011-2015
5.8.2 Future Strategies of MEDIPAL HOLDINGS CORPORATION: Revised Business Portfolio with Diverse Sources of Earnings
5.8.3 MEDIPAL HOLDINGS CORPORATION: Revenue Forecast, 2015-2026
5.9 Phoenix Group: Biggest European Wholesalers
5.9.1 The PHOENIX Group: Historical Performance, 2011-2015
5.9.2 Future Strategies of the PHOENIX Group: Selective Acquisition
5.9.3 The PHOENIX Group: Revenue Forecast, 2015-2026
5.10 SINOPHARM: The Leading Pharmaceutical Wholesaler and Distributor in China
5.10.1 SINOPHARM: Historical Performance, 2011-2015
5.10.2 Future Strategies of SINOPHARM: Provide Comprehensive Services and Wider Business Coverage
5.10.3 SINOPHARM: Revenue Forecast, 2015-2026
5.11 Alfresa Holdings: Second Largest Pharmaceutical Wholesaler and Distributor in Japan
5.11.1 Alfresa Holdings: Historical Performance, 2011-2015
5.11.2 Future Strategy of Alfresa Holdings: To Focus on Expanding Business Fields and Increasing Footprint
5.11.3 Alfresa Holdings: Revenue Forecast, 2015-2026
5.12 SUZUKEN CO., LTD: The First Nationwide Wholesaler of Japan
5.12.1 SUZUKEN CO. LTD: Historical Performance, 2011-2015
5.12.2 Future Strategies of SUZUKEN CO., LTD: Five Growth Initiatives and Special Focus on Diabetes Field
5.12.3 SUZUKEN CO., LTD: Revenue Forecast, 2015-2026
5.13 Shanghai Pharmaceuticals Holding: China’s Second Largest Wholesaler
5.13.1 Shanghai Pharmaceuticals Holding: Historical Performance, 2011-2015
5.13.2 Future Strategies of Shanghai Pharma: Expansion of Three Leading Regions in China
5.13.3 Shanghai Pharma: Revenue Forecast, 2015-2026

6. Qualitative Analysis of the Pharma Wholesale and Distribution Market
6.1 The Strengths and Weaknesses of the Pharma Wholesale and Distribution Market, 2016
6.1.1 The Insatiable Demand for Drugs: A Recession Proof Industry?
6.1.2 Wholesalers Do More than Deliver Drugs
6.1.2.1 Pre-Wholesaling: More Prevalent in Europe
6.1.2.2 Through Pre-Financing, Full-Line Wholesalers Finance the Entire Medicines Market
6.1.3 Large Companies Dominate the Market
6.1.4 Despite High Revenues, Profit Margins Are Low
6.1.5 Government-Induced Drug Price Pressures Restrict Profits
6.1.6 The Problem of Counterfeit Drugs
6.2 The Opportunities and Threats of the Pharma Wholesale and Distribution Market, 2015-2026
6.2.1 The Demand for Pharmaceuticals is Increasing
6.2.2 The Increasing Use of Specialty Drugs Will Drive Growth
6.2.3 The Increasing Use of Generic Drugs Will Limit Revenue, But Drive Profit Generation
6.2.4 The Promotion of Drug Therapy in the US
6.2.5 Globalisation: The Major National Markets are Dominated by Few Companies
6.2.6 Increased Adoption of the DTP Distribution Model
6.2.6.1 DTP in Europe: The First Place the Scheme Has Taken Hold
6.2.6.2 DTP in the UK Since 1991
6.2.6.3 DTP in Poland: The Second European Country To Adopt the DTP Model
6.2.6.4 Further Expansion of the DTP Model
6.2.7 The Threat of Healthcare Budget Cuts
6.2.7.1 Healthcare Budget Cuts in Germany
6.2.7.2 Healthcare Budget Cuts in France
6.2.7.3 Healthcare Budget Cuts in Italy
6.2.7.4 Healthcare Budget Cuts in Spain
6.2.7.5 Healthcare Budget Cuts in the UK
6.2.8 Do Large Pharmacy Chains Pose a Threat?
6.2.8.1 Case Study: Walmart and the $4 Prescription Scheme
6.2.8.2 Vertical Integration of Wholesalers: A Response to the Threat of Pharmacy Chains
6.2.9 Does the Diversion and Re-Importation of Medicines Pose a Threat to the Industry?
6.2.10 The Threat of Industry Consolidation
6.3 Social, Technological, Economical and Political Factors Influencing the Market, 2015-2026 (STEP Analysis)
6.3.1 Political Factor: The Impact of Recent Regulatory Changes in the EU
6.3.2 Political Factor: Combating Counterfeit Medicines
6.3.2.1 The US and E-Pedigree: Becoming Law in California
6.3.2.2 European Pedigree Legislation
6.3.2.3 Anti-Counterfeiting Strategies in Other Markets: The Chinese Government is Attempting to Address the Challenge
6.3.2.4 Serialisation for Wholesalers: Opportunity or a Challenge?

7. Research Interview
7.1 Interview with Mr Chris Frost, Sales Director of AAH Pharmaceuticals Ltd., (Celesio UK), Coventry
7.1.1 Current Status and Evolution of Pharma Wholesale and Distribution Market, UK
7.1.2 Driving Factors of the Pharma Wholesale and Distribution Market in the UK?
7.1.3 Future of the UK Pharma Wholesale and Distribution Market
7.1.4 Celesio UK Accounted for More than 60% of the Group’s Total Retail Pharmacy Business in 2013
7.1.5 The Outcome of McKesson’s Acquisition of Celesio AG
7.1.6 Prominent Business Segments of Celesio AG in the Future

8. Conclusions
8.1 The Future of the Pharma Wholesale and Distribution Market
8.2 The Leading National Pharma Wholesale and Distribution Markets
8.3 The Leading Companies in the Pharma Wholesale and Distribution Industry
8.4 Trends in the Pharma Wholesale and Distribution Industry
8.4.1 Generics Will Threaten Revenue
8.4.2 Manufacturers Will Deliver More Drugs Directly
8.4.3 There Will Be Greater Demand for Specialty Medicines
8.4.4 Consolidation Will Drive Growth
8.4.5 Anti-Counterfeiting Demands Will Add to Wholesalers’ Costs

List of Tables
Table 1.1 (Sample) The Global Pharma Wholesale and Distribution Industry and Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Top Company, 2015-2026
Table 1.2 Foreign Currency Exchange Rates to $US, 2015
Table 2.1 Use of DTP Model in the UK, 2007-2012
Table 3.1 Pharmaceutical Wholesale and Distribution: World Market Forecast ($bn), AGR (%), CAGR (%), 2015-2026
Table 3.2 Pharmaceutical Wholesale and Distribution: Branded Drugs, Generic Drugs and Others, Revenue ($bn) Forecasts, AGR (%), CAGR (%) and Market Shares (%), 2015-2026
Table 3.3 Wholesale and Distribution of Branded Drugs: Revenue ($bn) and Market Share (%) Forecast, 2015-2026
Table 3.4 Wholesale and Distribution of Generic Drugs: Revenue ($bn) and Market Share (%) Forecast, 2015-2026
Table 4.1 Pharma Wholesale & Distribution Leading National Markets: Revenues ($bn) and Market Share (%), 2015
Table 4.2 Pharma Wholesale & Distribution Leading National Markets: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2015-2026
Table 4.3 Revenue ($bn) and Market Share (%) Breakdown of the US Market: The 3 Leading Companies, 2015
Table 4.4 US Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
Table 4.5 Price Controls in Europe, 2015
Table 4.6 EU5 Pharma Wholesale & Distribution Market: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2015-2026
Table 4.7 German Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
Table 4.8 French Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
Table 4.9 Italian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
Table 4.10 Spanish Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
Table 4.11 UK Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
Table 4.12 Percentage of the Population Ages 60+ in the US, Europe, Japan, China and India, 2015 and 2030
Table 4.13 Japanese Pharmaceutical Wholesale and Distribution Market: Historical Sales ($bn) and Drug Price Revision Growth (%), 2006-2014
Table 4.14 Japanese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
Table 4.15 Chinese Pharma Wholesale & Distribution: Revenue ($bn) and Market Shares (%) of Leading Companies, 2015
Table 4.16 Chinese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
Table 4.17 Brazilian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
Table 4.18 Indian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
Table 4.19 Russian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
Table 5.1 Leading Companies in the Pharmaceutical Wholesale and Distribution Market: Revenues ($bn) and Market Shares (%), 2015
Table 5.2 Leading Pharmaceutical Wholesale and Distribution Companies: Revenue Forecasts ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.3 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%) for 2015, 2020 and 2026
Table 5.4 McKesson, Distribution Solutions: Services and Customers, 2016
Table 5.5 McKesson, Technology Solutions: Services and Customers, 2016
Table 5.6 McKesson: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2010-2015
Table 5.7 McKesson: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.8 McKesson: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.9 Acquisitions by McKesson, 2007-2016
Table 5.10 McKesson: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
Table 5.11 Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Operating Earnings ($bn), AGR (%) and CAGR (%), 2010-2015
Table 5.12 Cardinal Health: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.13 Cardinal Health: Operating Earnings ($bn) and Annual Growth (%) Breakdown by Business Segment, 2014-2015
Table 5.14 Cardinal Health: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2015
Table 5.15 Selected Acquisitions by Cardinal Health and their Line of Business, 2007-2016
Table 5.16 Cardinal Health: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
Table 5.17 AmerisourceBergen: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%) 2011-2015
Table 5.18 AmerisourceBergen: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.19 AmerisourceBergen: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.20 AmerisourceBergen: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2015
Table 5.21 Acquisitions by AmerisourceBergen and their Line of Business, 2007-2016
Table 5.22 AmerisourceBergen: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
Table 5.23 Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
Table 5.24 Walgreens Boots Alliance: Revenue ($bn), AGR (%), and CAGR (%) Forecast, 2015-2026
Table 5.25 MEDIPAL Holdings: Consolidated Subsidiary Companies, 2016
Table 5.26 MEDIPAL Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
Table 5.27 MEDIPAL Holdings: Revenue (¥bn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.28 MEDIPAL Holdings: Operating Income ($bn, ¥bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.29 MEDIPAL Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
Table 5.30 PHOENIX Group: Subsidiary Companies, 2015
Table 5.31 PHOENIX Group: Historical Revenue (€bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (€bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
Table 5.32 PHOENIX Group: Revenue (€bn, $bn), Revenue Share (%) Breakdown by Region, 2014
Table 5.33 PHOENIX Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
Table 5.34 SINOPHARM Group: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
Table 5.35 SINOPHARM Group: Revenue (RMBbn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.36 SINOPHARM Group: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.37 SINOPHARM Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
Table 5.38 Alfresa Holdings: List of Significant Subsidiaries and Affiliates, 2015
Table 5.39 Alfresa Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
Table 5.40 Alfresa Holdings: Sales Launches in the Manufacturing Business Segment, 2013-2014
Table 5.41 Alfresa Holdings: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.42 Alfresa Holdings: Gross Profit (¥bn, $bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.43 Alfresa Holdings: Targets of the 13-15 Medium-term Management Plan – The Challenge of Reform- Uniting to Climb New Peaks, 2015
Table 5.44 Alfresa Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
Table 5.45 SUZUKEN: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
Table 5.46 SUZUKEN: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.47 SUZUKEN: Operating Income (¥bn, $bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.48 SUZUKEN: Revenue (¥bn, $bn), Revenue Share (%) Breakdown for Pharmaceuticals Distribution Segment by Region, 2014
Table 5.49 SUZUKEN: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
Table 5.50 Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
Table 5.51 Shanghai Pharmaceuticals Holding: Revenue (RMBbn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.52 Shanghai Pharmaceuticals Holding: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.53 Shanghai Pharmaceuticals Holding: Distribution Revenue (RMBbn, $bn), Distribution Revenue Share (%) Breakdown by Region, 2015
Table 5.54 Shanghai Pharmaceuticals Holding: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
Table 6.1 The Pharmaceutical W&D Market: Strengths and Weaknesses, 2016
Table 6.2 The Pharmaceutical W&D Market: Opportunities and Threats, 2015-2026
Table 6.3 Strengths and Weaknesses of the DTP Distribution Model, 2015
Table 6.4 ITR Ratings and Corresponding Reimbursement Rates, 2015
Table 6.5 Social, Technological, Economic and Political Factors Influencing the Pharmaceutical Wholesale and Distribution Market (STEP Analysis), 2015-2026

List of Figures
Figure 1.1 Forecast Global Population Over the Age of 65 Years (millions), Annual Growth Rate (%), 2015-2026
Figure 1.2 Routes of Drug Distribution, 2016
Figure 2.1 Routes of Drug Distribution, 2016
Figure 3.1 The Global Pharmaceutical Wholesale and Distribution Market: Drivers and Restraints, 2016
Figure 3.2 Pharmaceutical Wholesale and Distribution: World Market Forecast ($bn), 2015-2026
Figure 3.3 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2015
Figure 3.4 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2020
Figure 3.5 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2026
Figure 3.6 Wholesale and Distribution of Branded Drugs, Generic Drugs and Others: Revenue Forecasts ($bn), 2015-2026
Figure 3.7 Wholesale and Distribution of Branded Drugs: Revenue ($bn) Forecast, 2015-2026
Figure 3.8 Wholesale and Distribution of Generic Drugs: Revenue ($bn) Forecast, 2015-2026
Figure 4.1 Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2015
Figure 4.2 Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2020
Figure 4.3 Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2026
Figure 4.4 Market Share (%) Breakdown of the US Market: The 3 Leading Companies, 2015
Figure 4.5 US Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
Figure 4.6 US Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016-2026
Figure 4.7 EU5 Pharma Wholesale & Distribution Market Shares (%), 2015, 2020 and 2026
Figure 4.8 EU5 Pharma Wholesale & Distribution Market: Revenue ($bn) Forecasts, 2015-2026
Figure 4.9 EU Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
Figure 4.10 German Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
Figure 4.11 German Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
Figure 4.12 French Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
Figure 4.13 French Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
Figure 4.14 Italian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
Figure 4.15 Italian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
Figure 4.16 Spanish Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
Figure 4.17 Spanish Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
Figure 4.18 UK Pharma Wholesale & Distribution Market: Revenue ($bn), 2015-2026
Figure 4.19 UK Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
Figure 4.20 Percentage of the Population Ages 65+ in the US, Europe, Japan, China and India, 2015 and 2030
Figure 4.21 Japanese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
Figure 4.22 Japanese Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
Figure 4.23 Chinese Pharma Wholesale & Distribution: Market Shares (%) of Leading Companies, 2015
Figure 4.24 Chinese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
Figure 4.25 Chinese Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
Figure 4.26 Brazilian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
Figure 4.27 Brazilian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
Figure 4.28 Pharma Wholesale & Distribution Model in India, 2016
Figure 4.29 Indian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
Figure 4.30 Indian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
Figure 4.31 Russian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
Figure 4.32 Russian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
Figure 5.1 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2015
Figure 5.2 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2020
Figure 5.3 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2026
Figure 5.4 Leading Pharmaceutical W&D Companies: Drivers and Restraints, 2016
Figure 5.5 McKesson: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2010-2015
Figure 5.6 McKesson: Revenue Share (%) Breakdown by Business Segment, 2015
Figure 5.7 McKesson: Gross Profit Share (%) Breakdown by Business Segment, 2015
Figure 5.8 McKesson: Revenue ($bn) Forecast, 2015-2026
Figure 5.9 McKesson: Drivers and Restraints, 2016-2026
Figure 5.10 Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Operating Earnings ($bn) and Operating Earnings AGR (%), 2010-2015
Figure 5.11 Cardinal Health: Revenue Share (%) Breakdown by Business Segment, 2015
Figure 5.12 Cardinal Health: Revenue Share (%) Breakdown by Customer, 2015
Figure 5.13 Cardinal Health: Revenue ($bn) Forecast, 2015-2026
Figure 5.14 Cardinal Health: Drivers and Restraints, 2015-2026
Figure 5.15 AmerisourceBergen: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2011-2015
Figure 5.16 AmerisourceBergen: Revenue Share (%) Breakdown by Business Segment, 2015
Figure 5.17 AmerisourceBergen: Revenue ($bn) Breakdown by Customer, 2015
Figure 5.18 AmerisourceBergen: Revenue ($bn) Forecast, 2015-2026
Figure 5.19 AmerisourceBergen: Drivers and Restraints, 2015-2026
Figure 5.20 Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2011-2015
Figure 5.21 Walgreens Boots Alliance: Revenue ($bn) Forecast, 2015-2026
Figure 5.22 Alliance Boots: Drivers and Restraints, 2015-2026
Figure 5.23 MEDIPAL Holdings: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn) and Gross Profit AGR (%), 2011-2015
Figure 5.24 MEDIPAL Holdings: Revenue Share (%) Breakdown by Business Segment, 2015
Figure 5.25 MEDIPAL Holdings: Operating Income Share (%) Breakdown by Business Segment, 2015
Figure 5.26 MEDIPAL Holdings: Revenue ($bn) Forecast, 2015-2026
Figure 5.27 MEDIPAL Holdings: Drivers and Restraints, 2015-2026
Figure 5.28 PHOENIX Group: Historical Revenue (€bn), Revenue AGR (%), Gross Profit (€bn) and Gross Profit AGR (%), 2011-2015
Figure 5.29 PHOENIX Group: Revenue Share (%) Breakdown by Region, 2014
Figure 5.30 PHOENIX Group: Revenue ($bn) Forecast, 2015-2026
Figure 5.31 PHOENIX Group Drivers and Restraints, 2015-2026
Figure 5.32 SINOPHARM Group: Historical Revenue (RMBbn), Revenue AGR (%), Gross Profit (RMBbn) and Gross Profit AGR (%), 2011-2015
Figure 5.33 SINOPHARM Group: Revenue ($bn) Forecast, 2015-2026
Figure 5.34 SINOPHARM Group: Drivers and Restraints, 2015-2026
Figure 5.35 Alfresa Holdings: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn), Gross Profit AGR (%), 2011-2015
Figure 5.36 Alfresa Holdings: Revenue Share (%) Breakdown by Business Segment, 2015
Figure 5.37 Alfresa Holdings: Gross Profit Share (%) Breakdown by Business Segment, 2015
Figure 5.38 Alfresa Holdings: Revenue ($bn) Forecast, 2015-2026
Figure 5.39 Alfresa Holdings: Drivers and Restraints, 2015-2026
Figure 5.40 SUZUKEN: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn) and Gross Profit AGR (%), 2011-2015
Figure 5.41 SUZUKEN: Revenue Share (%) Breakdown by Business Segment, 2015
Figure 5.42 SUZUKEN: Operating Income Share (%) Breakdown by Business Segment, 2015
Figure 5.43 SUZUKEN: Revenue Share (%) Breakdown by Region in Japan, 2014
Figure 5.44 SUZUKEN: Revenue ($bn) Forecast, 2015-2026
Figure 5.45 SUZUKEN: Drivers and Restraints, 2016-2026
Figure 5.46 Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn), Revenue AGR (%), Gross Profit (RMBbn) and Gross Profit AGR (%), 2011-2015
Figure 5.47 Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Business Segment, 2015
Figure 5.48 Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Region, 2015
Figure 5.49 Shanghai Pharmaceuticals Holding: Revenue ($bn) Forecast, 2015-2026
Figure 5.50 Shanghai Pharmaceuticals Holding: Drivers and Restraints, 2015-2026
Figure 6.1 Comparison of the Wholesale and DTP Routes of Distribution, 2016
Figure 6.2 Drug Pedigree Legislation: EU vs. US, 2015
Figure 8.1 Pharmaceutical Wholesale and Distribution: Global Market Forecasts ($bn) by Submarket, 2015-2026
Figure 8.2 Leading National Pharmaceutical Wholesale and Distribution Markets: Revenue Projections ($bn), 2015, 2020 and 2026
Figure 8.3 Leading Pharmaceutical Wholesale and Distribution Companies: Revenue ($bn) Projections 2015, 2020 and 2026

★調査レポート[医薬品卸売・物流の世界市場予測2016-2026] ( Pharma Wholesale and Distribution Market Forecasts 2016-2026 / VGAIN61117) 販売に関する免責事項
[医薬品卸売・物流の世界市場予測2016-2026] ( Pharma Wholesale and Distribution Market Forecasts 2016-2026 / VGAIN61117) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆